1 |
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48.
|
2 |
Kawiak A. Molecular research and treatment of breast cancer[J]. Int J Mol Sci, 2022, 23(17): 9617.
|
3 |
An JS, Peng C, Tang HL, et al. New advances in the research of resistance to neoadjuvant chemotherapy in breast cancer[J]. Int J Mol Sci, 2021, 22(17): 9644.
|
4 |
Barzaman K, Karami J, Zarei Z, et al. Breast cancer: biology, biomarkers, and treatments[J]. Int Immunopharmacol, 2020, 84: 106535.
|
5 |
Pancho A, Aerts T, Mitsogiannis MD, et al. Protocadherins at the crossroad of signaling pathways[J]. Front Mol Neurosci, 2020, 13: 117.
|
6 |
Yu JS, Koujak S, Nagase S, et al. PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer[J]. Oncogene, 2008, 27(34): 4657-65.
|
7 |
Harada H, Miyamoto K, Yamashita Y, et al. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer[J]. Cancer Med, 2015, 4(10): 1536-46.
|
8 |
Haruki S, Imoto I, Kozaki KI, et al. Frequent silencing of protocadherin 17, a candidate tumour suppressor for esophageal squamous cell carcinoma[J]. Carcinogenesis, 2010, 31(6): 1027-36.
|
9 |
Fang S, Huang SF, Cao J, et al. Silencing of PCDH10 in hepatocellular carcinoma via de novo DNA methylation independent of HBV infection or HBX expression[J]. Clin Exp Med, 2013, 13(2): 127-34.
|
10 |
Lei SY, Zheng RS, Zhang SW, et al. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020[J]. Cancer Commun, 2021, 41(11): 1183-94.
|
11 |
Chodosh LA. Breast cancer: current state and future promise[J]. Breast Cancer Res, 2011, 13(6): 113.
|
12 |
McDonald ES, Clark AS, Tchou J, et al. Clinical diagnosis and management of breast cancer[J]. J Nucl Med, 2016, 57(): 9S-16S.
|
13 |
Griguolo G, Pascual T, Dieci MV, et al. Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer[J]. J Immunother Cancer, 2019, 7(1): 90.
|
14 |
Vega-Benedetti AF, Loi E, Moi L, et al. Clustered protocadherins methylation alterations in cancer[J]. Clin Epigenetics, 2019, 11(1): 100.
|
15 |
Imoto I, Izumi H, Yokoi S, et al. Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers[J]. Cancer Res, 2006, 66(9): 4617-26.
|
16 |
Wang CL, Yu GZ, Liu JC, et al. Downregulation of PCDH9 predicts prognosis for patients with glioma[J]. J Clin Neurosci, 2012, 19(4): 541-5.
|
17 |
Zhen YL, Pavez M, Li XY. The role of Pcdh10 in neurological disease and cancer[J]. J Cancer Res Clin Oncol, 2023, 149(10): 8153-64.
|
18 |
Xia ZY, Huang MJ, Zhu QQ, et al. Cadherin related family member 2 acts As A tumor suppressor by inactivating AKT in human hepatocellular carcinoma[J]. J Cancer, 2019, 10(4): 864-73.
|
19 |
Okazaki N, Takahashi N, Kojima SI, et al. Protocadherin LKC, a new candidate for a tumor suppressor of colon and liver cancers, its association with contact inhibition of cell proliferation[J]. Carcinogenesis, 2002, 23(7): 1139-48.
|
20 |
Ose R, Yanagawa T, Ikeda S, et al. PCDH24-induced contact inhibition involves downregulation of beta-catenin signaling[J]. Mol Oncol, 2009, 3(1): 54-66.
|
21 |
Luo J, Yao JF, Deng XF, et al. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin αvβ3 and activating FAK/PI3K/AKT signaling[J]. J Exp Clin Cancer Res, 2018, 37(1): 23.
|
22 |
Spangle JM, Dreijerink KM, Groner AC, et al. PI3K/AKT signaling regulates H3K4 methylation in breast cancer[J]. Cell Rep, 2016, 15(12): 2692-704.
|
23 |
Xu JC, Chen TY, Liao LT, et al. NETO2 promotes esophageal cancer progression by inducing proliferation and metastasis via PI3K/AKT and ERK pathway[J]. Int J Biol Sci, 2021, 17(1): 259-70.
|
24 |
Wang Q, He GP, Hou MM, et al. Cell cycle regulation by alternative polyadenylation of CCND1[J]. Sci Rep, 2018, 8(1): 6824.
|
25 |
Hermosilla VE, Salgado G, Riffo E, et al. SALL2 represses cyclins D1 and E1 expression and restrains G1/S cell cycle transition and cancer-related phenotypes[J]. Mol Oncol, 2018, 12(7): 1026-46.
|
26 |
Feng YF, Qian WW, Zhang Y, et al. CDCA2 promotes the proliferation of colorectal cancer cells by activating the AKT/CCND1 pathway in vitro and in vivo [J]. BMC Cancer, 2019, 19(1): 576.
|
27 |
Xie ZZ, Li W, Ai JG, et al. C2orf40 inhibits metastasis and regulates chemo-resistance and radio-resistance of nasopharyngeal carcinoma cells by influencing cell cycle and activating the PI3K/AKT/mTOR signaling pathway[J]. J Transl Med, 2022, 20(1): 264.
|
28 |
Zhong Y, Yang LT, Xiong F, et al. Long non-coding RNA AFAP1-AS1 accelerates lung cancer cells migration and invasion by interacting with SNIP1 to upregulate c-Myc[J]. Signal Transduct Target Ther, 2021, 6(1): 240.
|
29 |
Kar G, Gursoy A, Keskin O. Human cancer protein-protein interaction network: a structural perspective[J]. PLoS Comput Biol, 2009, 5(12): e1000601.
|
30 |
Cho HJ, Hwang YS, Yoon J, et al. EphrinB1 promotes cancer cell migration and invasion through the interaction with RhoGDI1[J]. Oncogene, 2018, 37(7): 861-72.
|